Leerink Partnrs Comments on Kura Oncology Q1 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Kura Oncology in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of $0.15 per share for the quarter. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s FY2025 earnings at $0.15 EPS.

Several other brokerages also recently weighed in on KURA. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. UBS Group began coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective for the company. HC Wainwright upped their target price on Kura Oncology from $37.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Finally, Bank of America cut their price objective on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Stock Up 1.6 %

Shares of Kura Oncology stock opened at $8.79 on Monday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $683.55 million, a P/E ratio of -3.72 and a beta of 0.78. The firm’s 50 day moving average price is $8.69 and its 200-day moving average price is $14.87. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,255 shares of company stock worth $100,739. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in KURA. Thrivent Financial for Lutherans purchased a new stake in Kura Oncology during the fourth quarter worth $250,000. Corient Private Wealth LLC purchased a new position in Kura Oncology during the fourth quarter worth approximately $109,000. Wealthfront Advisers LLC purchased a new stake in shares of Kura Oncology in the fourth quarter valued at approximately $1,289,000. AlphaQuest LLC purchased a new position in shares of Kura Oncology during the 4th quarter valued at approximately $177,000. Finally, E Fund Management Co. Ltd. acquired a new stake in Kura Oncology in the 4th quarter valued at $90,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.